nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

17.01.2018 | review

Role of complement in the pathogenesis of thrombotic microangiopathies

verfasst von: Eszter Trojnár, Ágnes Szilágyi, Bálint Mikes, Dorottya Csuka, György Sinkovits, Prof. Zoltán Prohászka

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Summary

Thrombotic microangiopathies (TMAs) are rare but life-threatening disorders characterized by microvascular hemolytic anemia and acute thrombocytopenia with or without organ damage. The term TMA covers various subgroups of diseases, the pathogenesis of which is briefly summarized in this review. As highlighted here, complement activation may represent an important amalgamating process in all of these conditions, since it is able to link together activation and damage of multiple involved cell types, such as endothelial cells, platelets, and neutrophils.

Vorheriger Artikel Thrombotic thrombocytopenic purpura

Nächster Artikel Hemoglobinopathies—genetically diverse, clinically complex, and globally relevant

Warwicker P, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 1998;53(4):836–44.CrossRefPubMed

Szarvas N, et al. Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome. Mol Immunol. 2016;71:10–22.CrossRefPubMed

Caprioli J, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267–79.CrossRefPubMedPubMedCentral

Westra D, et al. Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H‑related 5 gene. J Hum Genet. 2012;57(7):459–64.CrossRefPubMedPubMedCentral

Jozsi M, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood. 2008;111(3):1512–4.CrossRefPubMed

Melton-Celsa AR. Shiga toxin (Stx) classification, structure, and function. Microbiol Spectr. 2014; https://doi.org/10.1128/microbiolspec.EHEC-0024-2013.CrossRefPubMed

Thurman JM, et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009;4(12):1920–4.CrossRefPubMedPubMedCentral

Stahl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood. 2011;117(20):5503–13.CrossRefPubMed

Westra D, et al. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr Nephrol. 2017;32(2):297–309.CrossRefPubMed

10.

Orth D, et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol. 2009;182(10):6394–400.CrossRefPubMed

11.

Arvidsson I, et al. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. J Immunol. 2015;194(5):2309–18.CrossRefPubMed

12.

Morigi M, et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol. 2011;187(1):172–80.CrossRefPubMed

13.

Del Conde I, et al. Platelet activation leads to activation and propagation of the complement system. J Exp Med. 2005;201(6):871–9.CrossRefPubMedPubMedCentral

14.

Bettoni S, et al. Interaction between multimeric von Willebrand factor and complement: a fresh look to the pathophysiology of microvascular thrombosis. J Immunol. 2017;199(3):1021–40.CrossRefPubMed

15.

Reti M, et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012;10(5):791–8.CrossRefPubMed

16.

Westwood JP, et al. Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura. Br J Haematol. 2014;164(6):858–66.CrossRefPubMedPubMedCentral

17.

Mikes B, et al. Elevated plasma neutrophil elastase concentration is associated with disease activity in patients with thrombotic thrombocytopenic purpura. Thromb Res. 2014;133(4):616–21.CrossRefPubMed

18.

Ruiz-Torres MP, et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost. 2005;93(3):443–52.PubMedCrossRef

19.

Jodele S, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013;122(12):2003–7.CrossRefPubMedPubMedCentral

20.

Gloude NJ, et al. Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD. Blood. 2017;130(10):1259–66.CrossRefPubMedPubMedCentral

21.

Yuen J, et al. NETosing neutrophils activate complement both on their own NETs and bacteria via alternative and non-alternative pathways. Front Immunol. 2016;7:137.CrossRefPubMedPubMedCentral

22.

Farkas P, et al. Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies. Immunobiology. 2017;222(2):119–27.CrossRefPubMed

23.

Cofiell R, et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015;125(21):3253–62.CrossRefPubMedPubMedCentral

24.

Azukaitis K, et al. The phenotypic spectrum of nephropathies associated with mutations in diacylglycerol kinase epsilon. J Am Soc Nephrol. 2017;28(10):3066–75.CrossRefPubMedPubMedCentral

25.

Balestracci A, et al. Blood urea nitrogen to serum creatinine ratio as a prognostic factor in diarrhea-associated hemolytic uremic syndrome: a validation study. Eur J Pediatr. 2017; https://doi.org/10.1007/s00431-017-2999-4.PubMedCrossRef

26.

Leffler J, et al. Decreased neutrophil extracellular trap degradation in Shiga toxin-associated haemolytic uraemic syndrome. J Innate Immun. 2017;9(1):12–21.CrossRefPubMed

27.

Lukasz A, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) in patients with Shiga toxin mediated haemolytic uraemic syndrome (STEC-HUS). Thromb Haemost. 2014;111(2):365–72.CrossRefPubMed

28.

Huang DT, et al. T‑antigen activation for prediction of pneumococcus-induced hemolytic uremic syndrome and hemolytic anemia. Pediatr Infect Dis J. 2006;25(7):608–10.CrossRefPubMed

29.

Szilagyi A, et al. The use of a rapid fluorogenic neuraminidase assay to differentiate acute streptococcus pneumoniae-associated hemolytic uremic syndrome (HUS) from other forms of HUS. Clin Chem Lab Med. 2015;53(4):e117–e9.CrossRefPubMed

30.

Mikes B, et al. Carboxiterminal pro-endothelin-1 as an endothelial cell biomarker in thrombotic thrombocytopenic purpura. Thromb Haemost. 2016;115(5):1034–43.CrossRefPubMed

31.

Bettoni G, et al. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012;10(8):1556–65.CrossRefPubMed

Titel: Role of complement in the pathogenesis of thrombotic microangiopathies
verfasst von: Eszter Trojnár
Ágnes Szilágyi
Bálint Mikes
Dorottya Csuka
György Sinkovits
Prof. Zoltán Prohászka
Publikationsdatum: 17.01.2018
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-017-0380-y

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Educational no. 2: flow cytometry

Current and evolving treatment strategies in adult immune thrombocytopenia

Demystification of palliative care: what palliative care teams don’t want you to think about them

Cure in metastatic breast cancer

Hemoglobinopathies—genetically diverse, clinically complex, and globally relevant

Cure in metastatic disease: how to manage and who is the right patient in GIST